Taxus Has Lower MACE Rate Than Cypher, American Journal of Cardiology Study
Wed, 17 Aug 2005 11:00 AM EST
... Angiotech Pharmaceuticals, Inc corporate partner, Boston Scientific ("BSC"),today welcomed the results of an independent study demonstrating that BSC''sTAXUS(R) Express2(TM) paclitaxel- eluting stent system had lower incidents ofmajor adverse cardiac events (MACE) than Johnson & Johnson''s Cypher(R)sirolimus-eluting stent system... click link for more info. ...
Related Topics
- Obstetrics
- Asian American
- Children's Health
- Ophthalmology
- Gynecology
- Epidemiology
- Bioethics
- Dermatology
- Psychopharmacology
- Epidemiology & Prevention of Vaccine-Preventable Diseases
- Incarceration
- American Sign Language
- Pharmacology
- American Indian
- Mental Retardation
- Telemedicine
- Infant Mortality
- African American
- African-American Health
- Sports Medicine

Not Signed In -


